Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

2021276 citationsReviewbronze Open Access

Authors

Mohamed Abou‐El‐Enein · University of Southern California

Magdi Elsallab · Children's Hospital of Los Angeles

Steven A. Feldman · Cancer Prevention Institute of California

Andrew D. Fesnak · Parker Institute for Cancer Immunotherapy

Helen E. Heslop · Methodist Hospital

Peter Marks · Center for Biologics Evaluation and Research

Brian G. Till

Abstract

As the demand for CAR T cell cancer therapy increases, several closed and automated production platforms are being deployed, and others are in development.This review provides a critical appraisal of these technologies that can be leveraged to scale and optimize the production of next generation CAR T cells.

Topics & Keywords

CAR-T cell therapy research Nanowire Synthesis and Applications Viral Infectious Diseases and Gene Expression in Insects

Publication Details

Published in: Blood Cancer Discovery

Volume 2, Issue 5, pp. 408-422

DOI: 10.1158/2643-3230.bcd-21-0084

Field-Weighted Citation Impact: 14.94

Command Palette

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Authors

Abstract

Topics & Keywords

Publication Details